Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules

Novartis Oncology, Basel, Switzerland.
Cancer Chemotherapy and Pharmacology (Impact Factor: 2.77). 06/2004; 53(5):433-8. DOI: 10.1007/s00280-003-0756-z
Source: PubMed


Imatinib (Glivec) has been established as a highly effective therapy for chronic myeloid leukemia and gastrointestinal tumors. The recommended daily dosage of 400-600 mg requires simultaneous intake of up to six of the current 100-mg capsules. Due to the need to swallow multiple capsules per dose, there is a potential negative impact on treatment adherence; therefore, a new imatinib 400-mg film-coated tablet has been developed. To improve dosing flexibility, particularly with regard to the pediatric population and the management of adverse events, a scored 100-mg film-coated tablet has also been introduced.
A group of 33 healthy subjects were randomly assigned to one of six treatment sequences, in which they received imatinib as 4 x 100-mg capsules (reference), 4 x 100-mg scored tablets (test), and 1 x 400-mg tablet (test). Blood sampling was performed for up to 96 h after dosing, followed by a 10-day washout period prior to the next sequence. After the third dosing, subjects were monitored to assess delayed drug-related adverse events. Pharmacokinetic parameters were assessed using concentration-time curves for plasma imatinib and its metabolite CGP74588.
Median Tmax was 2.5 h for capsules and tablets. Mean AUC((0-inf)) values were 27,094, 26,081 and 25,464 ng.h/ml for 4 x 100-mg capsules, 4 x 100-mg tablets, and 1 x 400-mg tablets, respectively. Cmax values were 1748, 1638 and 1606 ng/ml, and t(1/2) values were 15.8, 15.9 and 15.7 h. The test/reference ratios for AUC((0-inf)), AUC((0-96) (h)), and C(max) were 0.98, 0.98 and 0.95 for 4 x 100-mg tablets versus 4 x 100-mg capsules, and 0.95, 0.95 and 0.92 for 1 x 400-mg tablet versus 4 x 100-mg capsules. The 95% confidence intervals were fully contained within the interval (0.80, 1.25). Eight mild and one moderate adverse event considered to be drug related were reported. These events showed no clustering by type of dosage form and were of little to no clinical significance.
Film-coated 100-mg (scored) and 400-mg tablet dose forms of imatinib are bioequivalent to the commercial 100-mg hard-gelatin capsule, and are as safe and well tolerated.

90 Reads
    • "On the other hand, bioequivalence cannot be compromised when two solid dosage forms such as hard gelatin capsules and tablets where interchanged. Few publications are found in literature demonstrating potential interchangeability of two different solid dosage forms based on pharmacokinetic data[56]. The aim of the present study was to determine if the practice of interchangeability between two amoxicillin capsules (Amoxil®, 500 mg/capsule) and one amoxicillin tablet (Amoxicare®, 1000 mg/tablet) in order to achieve better patient compliance can be conducted without compromising their extent of absorption "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to evaluate if two capsules (Amoxil(®) capsules, 500 mg/capsule) and one tablet (Amoxicare(®) tablets, 1000 mg/tablet) of amoxicillin have similar bioequivalence parameters. For this purpose a randomized, two-way, crossover, bioequivalence study was performed in 24 healthy, male volunteers, divided into two groups of 12 subjects each. One group was treated with the reference standard (Amoxil(®)) and the other one with the generic tablet Amoxicare(®), with a crossover after a wash-out period of 7 days. Blood samples were collected at fixed time intervals and amoxicillin was determined by a validated HPLC method. The pharmacokinetic parameters AUC(0-8), AUC(0-∞), C(max), T(max), K(e) and T(1/2) were determined for both formulations and statistically compared to evaluate the bioequivalence between the two brands of amoxicillin, using the statistical model recommended by the FDA. C(max) and AUC(0-∞) were statistically analyzed using analysis of variance (ANOVA); no statistically significant difference was observed between the two formulations. The 90% confidence intervals between the mean values of C(max) and AUC(0-∞) fall within the FDA specified bioequivalent limits (80-125%) suggesting that the two products are bioequivalent and the two formulations are interchangeable. Based on these findings it was concluded that the practice of interchangeability between the above formulations to achieve better patient compliance could be followed without compromising the extent of amoxicillin absorption.
    Indian Journal of Pharmaceutical Sciences 07/2010; 72(4):414-20. DOI:10.4103/0250-474X.73904 · 0.48 Impact Factor
  • Source
    • "have reported on pharmacokinetic and pharmacodynamic properties as well as the overall tolerability and safety of imatinib in the plasma of CML patients (Peng et al., 2004b; Schmidli et al., 2005) and healthy volunteers (Nikolova et al., 2004), the data presented here include the complete characterization of the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [ 14 C]imatinib administration to healthy volunteers. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of (14)C-labeled imatinib mesylate. Biological fluids were analyzed for total radioactivity, imatinib, and its main metabolite CGP74588. Metabolite patterns were determined by radio-high-performance liquid chromatography with off-line microplate solid scintillation counting and characterized by liquid chromatography-mass spectrometry. Imatinib treatment was well tolerated without serious adverse events. Absorption was rapid (t(max) 1-2 h) and complete with imatinib as the major radioactive compound in plasma. Maximum plasma concentrations were 0.921 +/- 0.095 mug/ml (mean +/- S.D., n = 4) for imatinib and 0.115 +/- 0.026 mug/ml for the pharmacologically active N-desmethyl metabolite (CGP74588). Mean plasma terminal elimination half-lives were 13.5 +/- 0.9 h for imatinib, 20.6 +/- 1.7 h for CGP74588, and 57.3 +/- 12.5 h for (14)C radioactivity. Imatinib was predominantly cleared through oxidative metabolism. Approximately 65 and 9% of total systemic exposure [AUC(0-24 h) (area under the concentration time curve) of radioactivity] corresponded to imatinib and CGP74588, respectively. The remaining proportion corresponded mainly to oxidized derivatives of imatinib and CGP74588. Imatinib and its metabolites were excreted predominantly via the biliary-fecal route. Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine). Approximately 28 and 13% of the dose in the excreta corresponded to imatinib and CGP74588, respectively.
    Drug Metabolism and Disposition 11/2005; 33(10):1503-12. DOI:10.1124/dmd.105.004283 · 3.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. Although CYP3A4 has been reported to be the main enzyme in imatinib metabolism1, strong CYP3A4 inhibitors have had little effect on imatinib pharmacokinetics in vivo2,3. Recent data indicating that imatinib is a potent mechanism-based inhibitor of CYP3A4 in vitro4, suggests that imatinib can affect its own CYP3A4-mediated metabolism, reducing the importance of this enzyme in its pharmacokinetics. Methods. Based on in vitro metabolism data from recombinant CYP and human liver microsomal incubations, we constructed an in silico model for imatinib within the physiologically based pharmacokinetic (PBPK) simulator Simcyp. The final model for imatinib included first-order oral absorption, intestinal metabolism, a PBPK distribution model, and renal, hepatic and additional elimination for both unchanged imatinib and the main active metabolite, N-desmethylimatinib. Simulations were carried out aiming to evaluate the clinical importance of different CYP enzymes, in particular those of CYP2C8 and CYP3A4, in imatinib pharmacokinetics after a single dose versus multiple doses of imatinib. Results. The simulated imatinib mean peak concentration (Cmax) of 1600 ng/ml, mean time to reach Cmax of 2.5 h, and area under the plasma concentration-time curve (AUC)0-96 of 27000 ng∙h/ml, after a single dose of 400 mg imatinib, corresponded well with reference data5. According to the model, inactivation of CYP3A4 by imatinib progressed in a dose- and time-dependent manner, consequently affecting imatinib pharmacokinetics. On treatment day 1 with imatinib 400 mg once daily, the fractions metabolized by hepatic CYP2C8 and CYP3A4 were predicted to average 46% and 51%, respectively. After multiple doses at steady state, the importance of CYP2C8 was predicted to increase so that approximately 63% or 72% of imatinib was metabolized by CYP2C8 and 34% or 24% by CYP3A4 with 400 mg once or twice daily, respectively. Following a single 400 mg dose of imatinib, gemfibrozil (a strong CYP2C8 inhibitor; 600 mg twice daily), itraconazole (CYP3A4 inhibitor; 100 mg twice daily), and a combination of gemfibrozil and itraconazole were predicted to increase imatinib AUC0-∞ 1.9-, 1.4-, or 3.1-fold, respectively. However, when imatinib was at steady state, the AUC0-∞ increases were predicted to average 3.2- , 1.3-, or 4.9- fold, respectively. Conclusions. Although clinical studies are needed to confirm the present in vitro-in silico findings, it is likely that imatinib markedly affects its own CYP3A4-mediated metabolism via autoinhibition, assigning a key role for CYP2C8 in its elimination. Thus, during multiple dosing, imatinib may be sensitive to inhibition by CYP2C8 inhibitors such as gemfibrozil and trimethoprim. (1)European Medicines Agency. Summary_of_product_characteristics. (2012). (2)Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemoth Pharm 54[4]:290-4(2004). (3)van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 13[24]:7394-400(2007). (4)Filppula AM, Laitila J, Neuvonen PJ, Backman JT. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Brit J Pharmacol 165[8]:2787-98(2012). (5)Nikolova Z, Peng B, Hubert M, et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemoth Pharm 53[5]:433-8(2004).
    19th MDO and 12th European Regional International society for the study of xenobiotics Meeting;
Show more

Similar Publications